IndexIQ Advisors’s Edwards Lifesciences EW Stock Holding History

IndexIQ Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.3M	Sell	11,014 -54	-0.5%	-$6.06K	0.05%	249
2021 Q4	$1.43M	Sell	11,068 -308	-3%	-$35.9K	0.05%	254
2021 Q3	$1.29M	Buy	11,376 +506	+5%	+$57.8K	0.04%	274
2021 Q2	$1.13M	Buy	10,870 +168	+2%	+$15.8K	0.04%	271
2021 Q1	$895K	Buy	10,702 +2,054	+24%	+$174K	0.03%	275
2020 Q4	$789K	Buy	8,648 +4,059	+88%	+$337K	0.03%	270
2020 Q3	$366K	Buy	4,589 +2,756	+150%	+$215K	0.02%	348
2020 Q2	$127K	Buy	+1,833	New	+$130K	0.01%	819
2020 Q1	–	Sell	-219	Closed	-$17K	–	1078
2019 Q4	$17K	Buy	+219	New	+$17.1K	﹤0.01%	606

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IndexIQ Advisors's EW Position: Q1 2022 in Review

IndexIQ Advisors reduced its Edwards Lifesciences (EW) stake by 0.49% in Q1 2022, selling an estimated $6.06K and leaving 11,014 shares worth $1.3M. The position accounts for 0.05% of the portfolio, ranked #249.

IndexIQ Advisors first reported a position in EW in Q4 2019 and has held it in 9 quarters since. The position peaked at $1.43M in Q4 2021. 1,312 funds tracked by Wall St. Rank hold EW as of Q1 2022.

IndexIQ Advisors held 11,014 shares of Edwards Lifesciences worth $1.3M as of Q1 2022.
IndexIQ Advisors sold 54 Edwards Lifesciences shares in Q1 2022, an estimated $6.06K.
Edwards Lifesciences made up 0.05% of IndexIQ Advisors's portfolio in Q1 2022, its #249 holding.
IndexIQ Advisors first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 9 quarters since.
IndexIQ Advisors's Edwards Lifesciences position peaked at $1.43M in Q4 2021.
1,312 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.